ArticleCommunications medicine2024

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors.

Jian Jenny Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.